The Pediatric Praziquantel Consortium
The Pediatric Praziquantel Consortium was established in July 2012 and concluded its activities in 2026, having successfully completed its objectives. This website is maintained as an archive, providing continued access to information about the Consortium, its activities, and results.
The Pediatric Praziquantel Consortium was an international public-private partnership dedicated to reducing the global disease burden of schistosomiasis by addressing the medical needs of infected children between the ages of 3 months and 6 years. Through its work, the Consortium sought to contribute to ongoing efforts to eliminate schistosomiasis and improve child health.
-
Pediatric Praziquantel Consortium convenes in Utrecht for final meeting
Partners and funders of the Pediatric Praziquantel Consortium gathered in Utrecht in February for the final consortium meeting, marking an important milestone in more than a decade of collaboration. -
World NTD Day 2026: Turning Innovation into Impact through New Treatment for Preschoolers with Schistosomiasis
Today, 30 January, marks World Neglected Tropical Diseases (NTDs) Day, a global awareness day to recognize progress, renew commitment, and accelerate action to end NTDs. -
Pediatric Praziquantel Consortium nominated for Prix Galien Bridges Award for Best Public Sector Innovation
The Pediatric Praziquantel Consortium has been nominated for the 2025 Prix Galien Bridges Award in the Public Sector Innovation category. The Prix Galien Awards, often regarded as the “Nobel Prize for biopharmaceutical research,” recognize outstanding achievements that improve human health through scientific innovation.
-
Vision
To reduce the global disease burden of schistosomiasis by addressing the medical needs of infected preschool-aged children, including infants and toddlers. -
Mission
To develop, register, and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-aged children.
-
Development & registration program
The Consortium established a pediatric drug development program, divided into three major steps: preclinical development, clinical development, and registration & access. -
Access program
The Consortium developed an Access strategy by exploring new procurement and business models and conducting implementation research to support access to the new pediatric treatment for young patients in need.